|
KMID : 1001020060040020068
|
|
Journal of Urologic Oncology
2006 Volume.4 No. 2 p.68 ~ p.72
|
|
|
The Effects of BCG and Incidence of Urothelial Cancer Induced by N-butyl-N-(4-hydroxybutyl) Nitrosamine in Mouse
|
|
Kim Hyung-Jin
Kang Myoung-Jae
Kim Young-Gon
|
|
|
Abstract
|
|
|
Purpose: An experimental study was conducted to determine the incidence of urothelial cancer induced by N-butyl-N-(4-hydroxybutyl) nitrosamine(BBN) in mouse and the effects of intravesical BCG instillation to renal pelvis and bladder urothelial cancer.
Materials and Methods : Urothelial cancer of renal pelvis and bladder was induced by oral ingestion of 0.1% BBN for 12 weeks in female C3H/He mouse. After 12 weeks of carcinogen exposure, the animals were divided into two different groups. They received weekly intravesical instillation of 0.1ml normal saline(control group, n=21) or BCG(treatment group, n=14) for 4 weeks at 13-16 weeks. On 17 and 20 weeks, all animals were sacrificed. The tumor incidence between two groups was evaluated.
Results: The incidences of renal pelvis urothelial cancer in control and treatment groups were 19% and 7.1%, respectively(p=0.321). The incidences of bladder cancer at 17 weeks were 75%(n=12) and 0%(n=7), respectively(p＞0.05). At 20 weeks, bladder cancer incidences were 77.8%(n=9) and 28.6%(n=7), respectively(p＞0.05). However, the incidences of bladder cancer at 17 and 20 weeks were 76.2% and 14.3%, respectively(p＜0.05).
Conclusions : Intravesical BCG instillation in urothelial cancer induced by BBN does not decrease the incidence of renal pelvis cancer but reduces bladder cancer. These results suggest that BCG does not have systemic effects.
|
|
|
KEYWORD
|
|
|
Urothelial cancer, BCG, Animal model
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|